COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia

Affiliations

¹ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK.
² Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.
³ University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK.
⁴ Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK.
⁵ MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow G61 1QH, UK.
⁶ University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK.
⁷ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK. Electronic address: p.moss@bham.ac.uk.

Helen Parry et al. Cancer Cell. 2022.

. 2022 Jun 13;40(6):584-586.

doi: 10.1016/j.ccell.2022.05.001. Epub 2022 May 6.

¹ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK.
² Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.
³ University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK.
⁴ Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK.
⁵ MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow G61 1QH, UK.
⁶ University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK.
⁷ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK. Electronic address: p.moss@bham.ac.uk.

No abstract available

Conflict of interest statement

Declaration of interests The authors declare no conflicts of interest.

1. Collier A.Y., Yu J., McMahan K., Liu J., Chandrashekar A., Maron J.S., Atyeo C., Martinez D.R., Ansel J.L., Aguayo R., et al. Differential Kinetics of immune responses elicited by Covid-19 vaccines. New Engl. J. Med. 2021;385:2010–2012. - PMC - PubMed
1. Fendler A., Shepherd S.T.C., Au L., Wilkinson K.A., Wu M., Byrne F., Cerrone M., Schmitt A.M., Joharatnam-Hogan N., Shum B., et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat. Cancer. 2021:1–16. - PMC - PubMed
1. Greenberger L.M., Saltzman L.A., Senefeld J.W., Johnson P.W., DeGennaro L.J., Nichols G.L. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. Cancer cell. 2021;39:1297–1299. - PMC - PubMed
1. Herishanu Y., Rahav G., Levi S., Braester A., Itchaki G., Bairey O., Dally N., Shvidel L., Ziv-Baran T., Polliack A., et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood. 2022;139:678–685. - PMC - PubMed
1. Lim S.H., Stuart B., Joseph-Pietras D., Johson M., Campbell N., Kelly A., Jeffrey D., Turaj A.H., Rolfvondenbaumen K., Galloway C., et al. Immune Responses against SARS-CoV-2 Variants after Two and Three Doses of Vaccine in B-Cell Malignancies: UK PROSECO Study. Nature cancer. 2022 - PMC - PubMed